MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC)

Conditions:   Malignant Neoplasms of Urinary Tract;   Other Disorders of Kidney and Ureter;   Renal Cell Carcinoma Interventions:   Drug: MGCD516;   Drug: Nivolumab Sponsors:   M.D. Anderson Cancer Center;   Mirati Therapeutics Inc. Not yet recruiting - verified January 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials